Literature DB >> 36033145

New Research Aims to Optimize Therapy Against Onchocerciasis.

Augustine R Hong1, Nicholas O Opoku2, Gary J Weil3, Eric M Kanza4, Michael E Gyasi5.   

Abstract

Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis. Copyright 2022 by the Missouri State Medical Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36033145      PMCID: PMC9312456     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  12 in total

1.  Ophthalmic imaging by spectral optical coherence tomography.

Authors:  Maciej Wojtkowski; Tomasz Bajraszewski; Iwona Gorczyńska; Piotr Targowski; Andrzej Kowalczyk; Wojciech Wasilewski; Czesław Radzewicz
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

2.  The First Confirmed Elimination of an Onchocerciasis Focus in Africa: Abu Hamed, Sudan.

Authors:  Isam M A Zarroug; Kamal Hashim; Wigdan A ElMubark; Zainab A I Shumo; Kawthar A M Salih; Nuha A A ElNojomi; Huda A Awad; Nabil Aziz; Moses Katabarwa; Hassan K Hassan; Thomas R Unnasch; Charles D Mackenzie; Frank Richards; Tarig B Higazi
Journal:  Am J Trop Med Hyg       Date:  2016-06-27       Impact factor: 2.345

Review 3.  Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.

Authors:  María-Gloria Basáñez; Sébastien D S Pion; Eve Boakes; João A N Filipe; Thomas S Churcher; Michel Boussinesq
Journal:  Lancet Infect Dis       Date:  2008-05       Impact factor: 25.071

4.  Visual loss during oral diethylcarbamazine treatment for onchocerciasis.

Authors:  A C Bird; H El-Sheikh; J Anderson; H Fuglsang
Journal:  Lancet       Date:  1979-07-07       Impact factor: 79.321

5.  Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.

Authors:  B M Greene; H R Taylor; E J Brown; R L Humphrey; T J Lawley
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

6.  Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal.

Authors:  Mamadou O Traore; Moussa D Sarr; Alioune Badji; Yiriba Bissan; Lamine Diawara; Konimba Doumbia; Soula F Goita; Lassana Konate; Kalifa Mounkoro; Amadou F Seck; Laurent Toe; Seyni Toure; Jan H F Remme
Journal:  PLoS Negl Trop Dis       Date:  2012-09-13

7.  The global burden of disease study 2013: What does it mean for the NTDs?

Authors:  Jennifer R Herricks; Peter J Hotez; Valentine Wanga; Luc E Coffeng; Juanita A Haagsma; María-Gloria Basáñez; Geoffrey Buckle; Christine M Budke; Hélène Carabin; Eric M Fèvre; Thomas Fürst; Yara A Halasa; Charles H King; Michele E Murdoch; Kapa D Ramaiah; Donald S Shepard; Wilma A Stolk; Eduardo A Undurraga; Jeffrey D Stanaway; Mohsen Naghavi; Christopher J L Murray
Journal:  PLoS Negl Trop Dis       Date:  2017-08-03

8.  Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.

Authors:  Peter U Fischer; Christopher L King; Julie A Jacobson; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2017-01-05

9.  A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.

Authors:  Christopher L King; James Suamani; Nelly Sanuku; Yao-Chieh Cheng; Samson Satofan; Brooke Mancuso; Charles W Goss; Leanne J Robinson; Peter M Siba; Gary J Weil; James W Kazura
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

10.  The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.

Authors:  Gary J Weil; Joshua Bogus; Michael Christian; Christine Dubray; Yenny Djuardi; Peter U Fischer; Charles W Goss; Myra Hardy; Purushothaman Jambulingam; Christopher L King; Vijesh Sridhar Kuttiat; Kaliannagounder Krishnamoorthy; Moses Laman; Jean Frantz Lemoine; Katiuscia K O'Brian; Leanne J Robinson; Josaia Samuela; Kenneth B Schechtman; Anita Sircar; Adinarayanan Srividya; Andrew C Steer; Taniawati Supali; Swaminathan Subramanian
Journal:  PLoS Med       Date:  2019-06-24       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.